Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Mónica Arnedos"'
Autor:
James J. Harding, Sarina A. Piha-Paul, Ronak H. Shah, Jessica J. Murphy, James M. Cleary, Geoffrey I. Shapiro, David I. Quinn, Irene Braña, Victor Moreno, Mitesh Borad, Sherene Loi, Iben Spanggaard, Haeseong Park, James M. Ford, Mónica Arnedos, Salomon M. Stemmer, Christelle de la Fouchardiere, Christos Fountzilas, Jie Zhang, Daniel DiPrimeo, Casey Savin, S. Duygu Selcuklu, Michael F. Berger, Lisa D. Eli, Funda Meric-Bernstam, Komal Jhaveri, David B. Solit, Ghassan K. Abou-Alfa
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-12 (2023)
In biliary tract cancer HER2 alterations correlate with poor prognosis. Here, the authors present the results of a phase II clinical trial reporting the efficacy and safety of the tyrosine kinase inhibitor neratinib in patients with HER2-mutation pos
Externí odkaz:
https://doaj.org/article/6b0c6dc798b14d37bd9664bd41aec7e1
Autor:
Carlos L. Arteaga, Amparo Ruiz-Simon, Vicente Guillem, Mónica Arnedos, Fabrice André, Stefan Michiels, Mohamed Amine Bayar, Antonio Llombart-Cussac, Ana Lluch, J. Alejandro Perez-Fidalgo, Joaquín Gavilá, Alberto Servetto, Valerie M. Jansen, Monica V. Estrada, Jennifer M. Giltnane, Luis J. Schwarz, Kyung-Min Lee, Daniel G. Stover, Katherine E. Hutchinson, Luigi Formisano, Thomas P. Stricker, Angel L. Guerrero-Zotano
E2F4 gene signature modulation and association with overall survival in ER+/HER2- breast cancer treated with endocrine therapy. a) E2F4 gene signature expression at baseline (pre) and after 2-weeks of aromatase inhibitor treatment (post), data from A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e3f4a2f82ce09ea343f91d526ffa65c
https://doi.org/10.1158/1078-0432.22464813
https://doi.org/10.1158/1078-0432.22464813
Autor:
Carlos L. Arteaga, Amparo Ruiz-Simon, Vicente Guillem, Mónica Arnedos, Fabrice André, Stefan Michiels, Mohamed Amine Bayar, Antonio Llombart-Cussac, Ana Lluch, J. Alejandro Perez-Fidalgo, Joaquín Gavilá, Alberto Servetto, Valerie M. Jansen, Monica V. Estrada, Jennifer M. Giltnane, Luis J. Schwarz, Kyung-Min Lee, Daniel G. Stover, Katherine E. Hutchinson, Luigi Formisano, Thomas P. Stricker, Angel L. Guerrero-Zotano
Supplemental Table S1: The Preoperative Endocrine Prognostic Index (PEPI score) Supplemental Table S2:* Baseline Ki67: 7 patients had missing values Supplemental Table S3a: Driver Mutations Supplemental Table S3b: Driver Copy Number Alterations Suppl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ca888fa00d7bd81556fdcc0a854f431
https://doi.org/10.1158/1078-0432.22464807.v1
https://doi.org/10.1158/1078-0432.22464807.v1
Autor:
Carlos L. Arteaga, Amparo Ruiz-Simon, Vicente Guillem, Mónica Arnedos, Fabrice André, Stefan Michiels, Mohamed Amine Bayar, Antonio Llombart-Cussac, Ana Lluch, J. Alejandro Perez-Fidalgo, Joaquín Gavilá, Alberto Servetto, Valerie M. Jansen, Monica V. Estrada, Jennifer M. Giltnane, Luis J. Schwarz, Kyung-Min Lee, Daniel G. Stover, Katherine E. Hutchinson, Luigi Formisano, Thomas P. Stricker, Angel L. Guerrero-Zotano
Supplementary data information
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23dc8143c69eee8446250a02cdc65584
https://doi.org/10.1158/1078-0432.22464810.v1
https://doi.org/10.1158/1078-0432.22464810.v1
Autor:
Carlos L. Arteaga, Amparo Ruiz-Simon, Vicente Guillem, Mónica Arnedos, Fabrice André, Stefan Michiels, Mohamed Amine Bayar, Antonio Llombart-Cussac, Ana Lluch, J. Alejandro Perez-Fidalgo, Joaquín Gavilá, Alberto Servetto, Valerie M. Jansen, Monica V. Estrada, Jennifer M. Giltnane, Luis J. Schwarz, Kyung-Min Lee, Daniel G. Stover, Katherine E. Hutchinson, Luigi Formisano, Thomas P. Stricker, Angel L. Guerrero-Zotano
Purpose: This study aimed to identify biomarkers of resistance to endocrine therapy in estrogen receptor–positive (ER+) breast cancers treated with prolonged neoadjuvant letrozole.Experimental Design: We performed targeted DNA and RNA sequencing in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6aeb7a5cd0568c75f9155ae5ea115d85
https://doi.org/10.1158/1078-0432.c.6525807
https://doi.org/10.1158/1078-0432.c.6525807
Autor:
Yasmine Rhanine, Hervé Bonnefoi, Anthony Goncalves, Marc Debled, Sylvestre Le Moulec, Nathalie Bonichon, Gaetan Macgrogan, Monica Arnedos, Bénédicte Dubroca-Dehez, Thomas Grellety
Publikováno v:
Breast, Vol 73, Iss , Pp 103667- (2024)
Antiandrogens (AA) have been tested in clinical trials in androgen receptor (AR) + triple-negative breast cancer (TNBC). We aim to assess the clinical benefit rate (CBR) of AA in real life.The primary end-point was CBR at 6 months. Twenty-four patien
Externí odkaz:
https://doaj.org/article/344b27159eb14ac881aa9320bdf6aea4
Autor:
Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel Gonzalez-Perez, Mafalda Oliveira, Fara Brasó-Maristany, Nusaibah Ibrahimi, Srinivasaraghavan Kannan, Leonardo Mina, Maria Teresa Herrera-Abreu, Andreu Òdena, Mònica Sánchez-Guixé, Marta Capelán, Analía Azaro, Alejandra Bruna, Olga Rodríguez, Marta Guzmán, Judit Grueso, Cristina Viaplana, Javier Hernández, Faye Su, Kui Lin, Robert B. Clarke, Carlos Caldas, Joaquín Arribas, Stefan Michiels, Alicia García-Sanz, Nicholas C. Turner, Aleix Prat, Paolo Nuciforo, Rodrigo Dienstmann, Chandra S. Verma, Nuria Lopez-Bigas, Maurizio Scaltriti, Monica Arnedos, Cristina Saura, Violeta Serra
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-20 (2022)
CDK4/6 inhibitor resistance is common in breast cancer. Here, the authors show that p16 overexpression may be linked to reduced efficacy of CDK4/6 inhibition, and show that the combination with PI3K inhibitors may increase anti-tumour effects.
Externí odkaz:
https://doaj.org/article/c3a330e420d34dc992aab0ec2b80986a
Autor:
Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel Gonzalez-Perez, Mafalda Oliveira, Fara Brasó-Maristany, Nusaibah Ibrahimi, Srinivasaraghavan Kannan, Leonardo Mina, Maria Teresa Herrera-Abreu, Andreu Òdena, Mònica Sánchez-Guixé, Marta Capelán, Analía Azaro, Alejandra Bruna, Olga Rodríguez, Marta Guzmán, Judit Grueso, Cristina Viaplana, Javier Hernández, Faye Su, Kui Lin, Robert B. Clarke, Carlos Caldas, Joaquín Arribas, Stefan Michiels, Alicia García-Sanz, Nicholas C. Turner, Aleix Prat, Paolo Nuciforo, Rodrigo Dienstmann, Chandra S. Verma, Nuria Lopez-Bigas, Maurizio Scaltriti, Monica Arnedos, Cristina Saura, Violeta Serra
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-1 (2022)
Externí odkaz:
https://doaj.org/article/c47a0b935486445aafab933f5d652620
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
In late 2019 and early 2020, the world witnessed the outbreak of the SARS-CoV-2 (also referred as COVID-19) in Wuhan, China. Its rapid expansion worldwide and its contagiousness rate have forced the activation of several measures to contain the pande
Externí odkaz:
https://doaj.org/article/c20182755bdc4538916944a6573cf699
Autor:
Marion Bertho, Julien Fraisse, Anne Patsouris, Paul Cottu, Monica Arnedos, David Pérol, Anne Jaffré, Anthony Goncalves, Marie-Paule Lebitasy, Véronique D’Hondt, Florence Dalenc, Jean-Marc Ferrero, Christelle Levy, Sandrine Dabakuyo, Roman Rouzier, Frédérique Penault-Llorca, Lionel Uwer, Jean-Christophe Eymard, Mathias Breton, Michaël Chevrot, Sébastien Thureau, Thierry Petit, Gaëtane Simon, Jean-Sébastien Frénel
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Bone-only (BO) metastatic breast cancer (MBC) is considered a more favorable entity than other MBC presentations. However, only few retrospective series and data from selected randomized controlled trials have been reported so far. Method
Externí odkaz:
https://doaj.org/article/e5b9bcf3684642038d8891a42d6e9907